App Teaches Doctors to Diagnose Skin Cancer

Status Completed

Clinical Trial Summary

This study aimed to examine if self-paced learning with a novel digital patient-case-based educational platform can increase primary care physicians' diagnostic accuracy of malignant and benign skin lesions on both the level of benign/malignant and the diagnosis level. Secondarily the study aimed to investigate the time spent in reaching this change in proficiency.

Clinical Trial Description

Participants were given a questionnaire and an initial Skin Cancer Multiple Choice-Questionnaire (MCQ) to test their diagnostic skills regardining skin and mole cancer and the most common differential diagnoses. Participants in the Intervention group was then given access to an educational mobile application (App) for 8 days and asked to diagnose 500 patient cases. The participants did so at their own leisure and time. After 8 days they were asked to abstain from using the App for another 8 days (wash out period) and were then given a Final Skin Cancer Multiple Choice-Questionnaire (MCQ). Participants of the control group received no intervention nor education during the 16 days of waiting before they took the final Skin Cancer Multiple Choice-Questionnaire. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05661370
Study type	Interventional
Source	Herlev Hospital
Contact
Status	Completed
Phase	N/A
Start date	November 15, 2021
Completion date	August 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04062032` - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma	Phase 2
Completed	`NCT03620019` - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma	Phase 2
Active, not recruiting	`NCT03291002` - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC	Phase 1
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A
Completed	`NCT00962845` - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery	Early Phase 1
Completed	`NCT00324623` - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma	Phase 1
Completed	`NCT00096382` - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00104845` - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	Phase 1
Completed	`NCT00072124` - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma	Phase 3
Completed	`NCT00072085` - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00089193` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	Phase 2
Active, not recruiting	`NCT00039234` - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver	Phase 3
Completed	`NCT00049010` - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma	N/A
Completed	`NCT00042783` - Vaccine Therapy in Treating Patients With Stage IV Melanoma	Phase 2
Completed	`NCT00006385` - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00005610` - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung	Phase 2
Completed	`NCT00006022` - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer	Phase 1
Completed	`NCT00020358` - Vaccine Therapy in Treating Patients With Melanoma	Phase 2
Recruiting	`NCT03767348` - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab	Phase 2
Withdrawn	`NCT00006126` - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery	Phase 1